Nanoparticle-based modulation of CD4<sup>+</sup> T cell effector and helper functions enhances adoptive immunotherapy.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 36241639.
- Also identified by DOI 10.1038/s41467-022-33597-y and PMC identifier 9568616.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Helper (CD4<sup>+</sup>) T cells perform direct therapeutic functions and augment responses of cells such as cytotoxic (CD8<sup>+</sup>) T cells against a wide variety of diseases and pathogens. Nevertheless, inefficient synthetic technologies for expansion of antigen-specific CD4<sup>+</sup> T cells hinders consistency and scalability of CD4<sup>+</sup> T cell-based therapies, and complicates mechanistic studies. Here we describe a nanoparticle platform for ex vivo CD4<sup>+</sup> T cell culture that mimics antigen presenting cells (APC) through display of major histocompatibility class II (MHC II) molecules. When combined with soluble co-stimulation signals, MHC II artificial APCs (aAPCs) expand cognate murine CD4<sup>+</sup> T cells, including rare endogenous subsets, to induce potent effector functions in vitro and in vivo. Moreover, MHC II aAPCs provide help signals that enhance antitumor function of aAPC-activated CD8<sup>+</sup> T cells in a mouse tumor model. Lastly, human leukocyte antigen class II-based aAPCs expand rare subsets of functional, antigen-specific human CD4<sup>+</sup> T cells. Overall, MHC II aAPCs provide a promising approach for harnessing targeted CD4<sup>+</sup> T cell responses.
Medical subject headings
- Immunotherapy, Adoptive
- Nanoparticles